Collect Product
Product Details
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureBinding Capacity>267 pmol (40 μg) antibody/mg beads>267 pmol (40 μg) antibody/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
Product Description
The biotinylated BCMA protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-BCMA antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This Human BCMA-coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C. Once reconstitution, please aliquote and store under -70°C for no more than 3 months, and avoid repeated freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
Assay Principles
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Typical Data
Add BCMA pre-coupling magnetic beads into each well at a concentration of 1 mg/ml. 0.1 mg beads was added to each well. Then add increasing concentrations of anti-BCMA antibody to different wells. PE-labeled anti-human IgG Fc antibody was used for detection.
Protocol
The binding curves between BCMA pre-coupling magnetic beads (Cat. No. MBS-K004) after different freeze-thaw cycles and anti-BCMA antibody. 0.1 mg of Beads (1 mg/mL, 100 μL) was washed three times and the supernatant was removed. 100 μL antibodies of the corresponding concentration (10 μg/mL-0.039 μg/mL) were added. Fluorescent labeled secondary antibody was added for detection (Routinely tested).
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Frontier Progress
Drug Development Progress- English Name：
B-cell maturation protein
- Category：
- Listed Drugs Count：
8 Details
- Clinical Drugs Count：
145 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
